VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)

December 10, 2012 9:10 AM EST
Get Alerts VVUS Hot Sheet
Price: $1.19 +2.59%

Rating Summary:
    4 Buy, 8 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VVUS Now!
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is ticking higher in early trading Monday following reports that Qsymia prescriptions rose following the Thanksgiving holiday.

According to Bloomberg Industries-compiled data, prescriptions to the weight-loss drug rose 21 percent in the week ended November 29th.

BI thinks Thanksgiving boosted overall demand, with retail prescriptions rising 19 percent sequentially. Qsymia prescriptions fell 6 percent during the week of Thanksgiving.

Shares of VIVUS are indicated 2 percent higher Monday morning. Traders are likely to keep an eye on Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) following the news. Both are key players in the obesity pill game along with VIVUS.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment